OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


2003 Individual Investigator Grant Recipient – Parameshwar Mahareshti

Parameshwar Mahareshti, DVM
University of Alabama, Birmingham
ANew Combination Drug Treatments for Ovarian Cancer

Project Summary

Despite the high initial response rates of patients with advanced ovarian cancer to aggressive primary surgical debulking followed by chemotherapy , the disease will recur in most patients. The high degree of relapse and relative incurability after is due to the genetic instability and high mutation rate of ovarian cancer cells, which together create drug resistance. Previous studies have reported that targeting the genetically stable endothelial cells of newly formed tumor blood vessels by anti-angiogensis drugs, or agents that prevent blood vessel growth, may offer a novel way to circumvent drug resistance. Studies have shown that VEGF, or vascular endothelial growth factor, affects other pathways in the cancer cell that make the cell resistant to chemotherapeutic drugs, such as paclitaxel. Therefore, drugs that stop VEGF in combination with chemotherapy may offer a novel approach to achieve more effective chemotherapeutic response for ovarian carcinoma.